TY  - JOUR
AU  - van Brummelen, Emilie M J
AU  - Levchenko, Evgeny
AU  - Dómine, Manuel
AU  - Fennell, Dean A
AU  - Kindler, Hedy L
AU  - Viteri, Santiago
AU  - Gadgeel, Shirish
AU  - López, Pilar Garrido
AU  - Kostorov, Vladimir
AU  - Morgensztern, Daniel
AU  - Orlov, Sergey
AU  - Zauderer, Marjorie G
AU  - Vansteenkiste, Johan F
AU  - Baker-Neblett, Katherine
AU  - Vasquez, James
AU  - Wang, Xiaowei
AU  - Bellovin, David I
AU  - Schellens, Jan H M
AU  - Yan, Li
AU  - Mitrica, Ionel
AU  - DeYoung, M Phillip
AU  - Trigo, Jose
PY  - 2019
DO  - 10.1007/s10637-019-00783-7
UR  - http://hdl.handle.net/10668/13925
T2  - Investigational new drugs
AB  - Background Fibroblast growth factors (FGFs) have a fundamental role in cancer. Sequestering FGFs with GSK3052230 (FP-1039) blocks their ability to activate FGFRs while avoiding toxicities associated with small molecule inhibitors of FGFR, including...
LA  - en
PB  - Springer Nature
KW  - Combination therapy
KW  - FGF
KW  - Ligand trap
KW  - Mesothelioma
KW  - Phase 1
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Agents
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Cisplatin
KW  - Female
KW  - Fibroblast Growth Factor 2
KW  - Humans
KW  - Immunoglobulin G
KW  - Ligands
KW  - Male
KW  - Mesothelioma, Malignant
KW  - Middle Aged
KW  - Oncogene Proteins, Fusion
KW  - Pemetrexed
KW  - Receptor, Fibroblast Growth Factor, Type 1
KW  - Recombinant Fusion Proteins
KW  - Treatment Outcome
TI  - A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.
TY  - research article
VL  - 38
ER  -